U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. Drugs
  3. Development & Approval Process | Drugs
  4. How Drugs are Developed and Approved
  5. Types of Applications
  6. Abbreviated New Drug Application (ANDA)
  7. Generic Drug Development
  1. Abbreviated New Drug Application (ANDA)

Generic Drug Development

Register to learn about sustainability in inhaler technology Dec. 4-5
Our “Navigating the Transition to Low Global Warming Potential Propellants” workshop will cover the shift from current technology.

Generic Drug Approvals

FDA regularly updates its lists of first generic drug approvals and competitive generic therapy approvals. To view all generic drug approvals and tentative approvals, use the “Drug Approval Reports by Month” feature on Drugs@FDA and select “Original Abbreviated New Drug Approvals (ANDAs) by Month” for generic drug approvals or “Tentative Approvals by Month” for tentative approvals. This database is updated daily.

Generic Drug Regulatory Resources

Contact FDA

Potential ANDA applicants are encouraged to contact the FDA Generic Drugs Program with questions at any point in their development and application preparation processes.

If you have specific questions regarding the development of a generic drug product not yet submitted in an ANDA, please submit a controlled correspondence.

If you have a general question about generic drugs, please email druginfo@fda.hhs.gov.

If you have a question regarding an ANDA for which you are the applicant or authorized representative, please contact the regulatory project manager assigned to the application.

Additional Generic Drugs Program assistance resources are available at GDUFA Points of Contact.

Office of Generic Drugs
10903 New Hampshire Avenue
Silver Spring, MD 20993
240-402-7920
301-595-1147 Fax

Back to Top